Gold Deals and Drill Hits Drive ASX Week 19

Caprice Resources (ASX:CRS) topped the board with a 68.83% weekly gain after reporting 22 metres at 66.2 grams a tonne gold from a new near-surface zone at Island. Investors cared because the result points to more than one gold lode, which can mean a larger deposit and more drilling targets. X2M Connect (ASX:X2M) rose 50.00% on its smart community plan with Mawson, tying AI software to private 5G networks for retirement villages. At the other end, ImpediMed (ASX:IPD) dropped 46.43% after unveiling a A$15.2 million capital raising and a plan to cut costs. Investors were worried because new shares were issued at a low price, which can reduce the value of existing holdings.

Gold stays at the centre

Gold names filled much of the winners list. Great Boulder Resources (ASX:GBR) climbed 25.00% after locking in the Peak Hill Gold Project deal and a A$40 million placement to fund drilling and a push towards near-term production. Gorilla Gold Mines (ASX:GG8) added 19.44% after discovering a new high-grade lode at Comet Vale. Scorpion Minerals (ASX:SCN) lifted 17.86% on a new exploration target at Old Prospect. Larger gold names were active too. Regis Resources (ASX:RRL) and Vault Minerals (ASX:VAU) agreed to merge in a deal that would create Australia’s third-largest ASX-listed gold producer. The combined group is expected to produce more than 700,000 ounces a year and hold about A$1.9 billion in cash and bullion with no debt. That matters because scale can lower costs, improve access to funding and make operations less reliant on one mine.

Funding moves split the market

Fresh capital did not produce the same result everywhere. Waratah Minerals (ASX:WTM) raised A$48 million to speed up drilling at Spur. Tanami Gold (ASX:TAM) announced a fully underwritten rights issue to raise A$70.5 million for the Central Tanami Project, but the stock fell 15.05%. The issue price was well below the last traded price, and that often worries investors because non-participants can be diluted. Elsewhere, WA Kaolin (ASX:WAK) launched a A$34.9 million entitlement offer to cut debt and improve plant performance. Core Lithium (ASX:CXO) completed the second tranche of its equity raising to support Finniss. In plain terms, many companies are using stronger windows in the market to refill the bank account before the next stage of building, drilling or commissioning.

Data centres and digital infrastructure kept attracting buyers

Infrastructure names tied to data storage and computing had another strong week. Infratil-backed CDC, traded through Infratil (ASX:IFT), gained 18.66% after securing a 555MW data centre contract with a US investment grade customer. It is a huge power commitment over 30 years, and investors liked the clear revenue visibility. NEXTDC (ASX:NXT) rose 3.79% after securing A$1.8 billion in senior debt and then completing a A$1.7 billion hybrid securities offer. The company now says pro forma liquidity, meaning cash and available funding, is about A$8.4 billion. Investors care because data centres are expensive to build, and funding certainty lowers the risk of delays.

Results season rewarded clear earnings growth

Several larger companies advanced on strong numbers. Macquarie Group (ASX:MQG) reported a 30% rise in FY2026 net profit to A$4.85 billion and maintained solid capital ratios. Navigator Global Investments (ASX:NGI) jumped 9.26% after announcing a US$195 million acquisition and a A$145 million entitlement offer, with management saying the deal should add to earnings in the first full year. FleetPartners (ASX:FPR) rallied 18.22% after reporting profit growth, strong cash generation and an interim dividend. Smartgroup (ASX:SIQ) rose 16.61% as novated leasing orders climbed. These updates were easier for investors to trust because they came with revenue, profit or cash figures rather than early-stage promises.

Biotech and small caps remained volatile

Healthcare names showed how quickly sentiment can turn. Entropy Neurodynamics (ASX:ENP) drew interest after reporting a 75% response rate in a small Phase 2a trial for treatment-resistant IBS and then filing a new US patent application. In simple terms, the company says many patients improved and it is trying to protect the idea legally. Even so, the stock finished the week down 1.35%, which shows investors still want bigger trials and more proof. Some gap movers also told a mixed story. A few stocks held onto most of their reopening gains, which suggests sustained buying after news landed. Others gave back ground after an early jump, meaning traders took quick profits or doubted the news would change earnings soon. That pattern was visible in several micro-caps across technology, biotech and resources, where liquidity is thin and price moves can be exaggerated.